

# Prognostic Effect of Insertion/Deletion Polymorphism of the ACE Gene on Renal and Cardiovascular Clinical Outcomes in Chinese Patients With Type 2 Diabetes

YING WANG, PHD  
MAGGIE C.Y. NG, BSC, PHD  
WING YEE SO, MBCHB, MRCP  
PETER C.Y. TONG, PHD, FRCP

RONALD C.W. MA, MBBCHIR, MRCP  
CHUN CHUNG CHOW, MBBS, FRCP  
CLIVE S. COCKRAM, MD, FRCP  
JULIANA C.N. CHAN, MD, FRCP

**OBJECTIVE** — The insertion/deletion (I/D) polymorphism of the ACE gene has been reported to be associated with diabetic microvascular or macrovascular complications. The aim of the present study was to investigate the prognostic effect of I/D polymorphism on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes.

**RESEARCH DESIGN AND METHODS** — A consecutive cohort of 1,281 Chinese patients with type 2 diabetes were followed for  $41.3 \pm 21.6$  months. Renal end points were defined as renal death and events (need for dialysis, plasma creatinine  $\geq 500 \mu\text{mol/l}$ , or doubling of plasma creatinine of baseline value  $\geq 150 \mu\text{mol/l}$ ). Cardiovascular end points were defined as cardiovascular death and events, which included ischemic heart disease, heart failure, cerebrovascular accident, and revascularization requiring hospital admission. The I/D polymorphism of the ACE gene was examined by PCR followed by agarose gel electrophoresis.

**RESULTS** — The frequencies of ACE gene I/D polymorphisms were in Hardy-Weinberg equilibrium. Patients who developed a renal end point ( $n = 98$ ) had higher frequencies of DD genotype (19.4 vs. 10.8%,  $P = 0.018$ ) and D allele (41.3 vs. 31.8%,  $P = 0.006$ ) compared with subjects who did not ( $n = 1,183$ ). The cumulative rates of renal end points were 10.0, 19.2, and 24.4% in the II ( $n = 595$ ), DI ( $n = 539$ ), and DD genotype carriers ( $n = 147$ ), respectively (log rank  $P = 0.004$ ). In multiple Cox regression analysis, the occurrence of renal end points remained significantly influenced by I/D polymorphism with a dominant deleterious effect of the DD genotype (DD versus II, adjusted hazard ratio 2.80 [95% CI 1.49–5.29]). There was no prognostic effect of I/D polymorphism on cardiovascular end points.

**CONCLUSIONS** — The DD genotype of the ACE I/D polymorphism was an independent risk factor for renal but not cardiovascular end points in Chinese patients with type 2 diabetes.

*Diabetes Care* 28:348–354, 2005

**A**CE is one of the key enzymes in the renin-angiotensin system, which plays an important role in fluid and electrolyte balance and regulation of blood pressure and cellular growth (1,2). The human ACE gene is located in chromosome 17q23 with 26 exons and 25 introns with an insertion/deletion (I/D)

polymorphism that comprises a 278-bp fragment in intron 16 (3). The DD genotype or D allele of this polymorphism was shown to be associated with elevated circulating and tissue ACE activity (4) as well as increased risk of hypertension (5) and diabetic renal (6) and cardiovascular complications (7). However, these results remained inconsistent in both Caucasian (8–11) and non-Caucasian populations, including Chinese (12,13). These discrepancies might be due to ethnicity, study design, patient selection criteria, and small sample size. The aim of the present study was to evaluate the prognostic effect of this polymorphism on renal and cardiovascular outcomes in a large cohort of 1,281 Chinese patients with type 2 diabetes.

## RESEARCH DESIGN AND METHODS

The Prince of Wales Hospital is the teaching hospital of the Chinese University of Hong Kong. It serves a population of over 1.2 million. Since 1995, as part of a continuous quality improvement program, all newly referred patients to the clinic underwent a comprehensive assessment of complications and risk factors based on the European DiabCare protocol (14). Clinical assessments included measurement of BMI, waist-to-hip ratio, and blood pressure as well as documentation of visual acuity and examination by funduscopy through dilated pupils. For the foot examination, we used monofilament and graduated tuning forks to assess sensory neuropathy. Fasting blood samples were taken for measurement of plasma glucose, HbA<sub>1c</sub>, lipids (total cholesterol), HDL cholesterol, triglycerides, and plasma creatinine. A sterile, random spot urine sample was used to measure albumin-to-creatinine ratio (ACR) followed by a timed collection (4 or 24 h) for albumin excretion rate (AER). Using the ACR from these two samples, normoalbuminuria was defined as a mean ACR  $\leq 3.5 \text{ mg}$

From the Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.

Address correspondence and reprint requests to Juliana C.N. Chan, MD, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR. E-mail: jchan@cuhk.edu.hk

Received for publication 20 November 2003 and accepted in revised form 18 September 2004.

**Abbreviations:** ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; I/D, insertion/deletion.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Table 1—Baseline clinical and biochemical characteristics of Chinese patients with type 2 diabetes divided according to their ACE I/D genotype**

	II	DI	DD	P
n	595	539	147	
Sex (% women)	44.5	41.5	36.2	0.156
Age (years)	61.0 ± 12.2	60.9 ± 12.2	61.3 ± 10.9	0.928
Duration of diabetes (years)	8.4 ± 6.5	8.4 ± 6.6	8.6 ± 6.5	0.907
BMI (kg/m <sup>2</sup> )	24.7 ± 3.7	24.7 ± 3.9	25.0 ± 3.6	0.705
Waist-to-hip ratio	0.89 ± 0.06	0.89 ± 0.09	0.88 ± 0.06	0.778
Systolic blood pressure (mmHg)	138 ± 23	137 ± 23	139 ± 22	0.561
Diastolic blood pressure (mmHg)	79 ± 11	79 ± 11	80 ± 11	0.632
HbA <sub>1c</sub> (%)	7.7 (6.7–9.2)	7.5 (6.6–8.8)	7.4 (6.7–8.5)	0.581
Fasting plasma glucose (mmol/l)	8.0 (6.5–10.5)	8.0 (6.4–10.5)	8.4 (6.5–10.7)	0.811
Total cholesterol (mmol/l)	5.5 ± 1.2	5.6 ± 1.3	5.6 ± 1.2	0.454
Triglycerides (mmol/l)	1.38 (0.95–2.06)	1.37 (0.88–2.10)	1.35 (0.94–2.12)	0.941
HDL cholesterol (mmol/l)	1.20 (1.01–1.46)	1.23 (1.01–1.53)	1.22 (1.03–1.39)	0.347
LDL cholesterol (mmol/l)	3.4 ± 1.0	3.5 ± 1.1	3.5 ± 0.9	0.470
Plasma creatinine (μmol/l)	75 (61–96)	75 (61–97)	78 (64–99)	0.099
Urinary ACR (mg/mmol)	2.1 (0.7–37.7)	1.7 (0.6–34.6)	2.0 (0.8–35.3)	0.973
Urinary AER (μg/min)	21.3 (8.8–319.0)	20.2 (8.8–489.0)	16.7 (9.8–450.0)	0.784
Serum ACE activity (units/l)*	46.3 ± 38.6	56.8 ± 21.3	63.9 ± 21.9	<0.001
Use of lipid-lowering drugs (%)	32.4	31.5	35.5	0.226
Use of antihypertensive drugs (%)	24.0	24.7	29.6	0.652
Ophthalmic complications (%)†	38.2	36.0	32.2	0.355
Sensory neuropathy (%)	24.0	23.5	28.9	0.518
Cardiovascular complications (%)‡	14.7	13.7	18.4	0.346

Data are means ± SD or median (interquartile range). P value is the significance of ANCOVA or  $\chi^2$  test. \*Serum ACE activity was available in 399 patients. †Ophthalmic complications were defined as diabetic retinopathy, glaucoma, or cataract with impaired visual acuity <20/70 in the same eye. ‡Cardiovascular complications were defined as ischemic heart disease, cerebrovascular disease, and/or peripheral vascular disease.

mmol; microalbuminuria was defined as ACR between 3.5 and 25 mg/mmol; and macroalbuminuria was defined as ACR  $\geq$ 25 mg/mmol (15). The procedures related to the study were approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. Informed consent was obtained from all participants.

Between July 1994 and June 1998, a consecutive cohort of 1,281 Chinese patients with type 2 diabetes underwent detailed assessments using the above protocol. Patients with type 1 presentation, defined as diabetic ketoacidosis, acute presentation with heavy ketonuria (>3+), or continuous requirement of insulin within 1 year of diagnosis (16), were excluded. Mortality and clinical outcomes were ascertained in May 2001. Mortality data obtained from the Hong Kong Death Registry were further ascertained by review of case notes. Details of all medical admissions with primary and secondary diagnosis as well as medication history and last available plasma creatinine results were retrieved from the Central Computerized System at the Hospital Authority Head Office, which captures

>90% of these data from all public hospitals in Hong Kong. Cardiovascular end points were defined as hospitalizations due to ischemic heart disease, heart failure, cerebrovascular accident, and revascularization procedures. Renal end points were defined as dialysis or doubling of plasma creatinine if the baseline value was  $\geq$ 150  $\mu$ mol/l or the absolute value was  $\geq$ 500  $\mu$ mol/l.

#### Laboratory assays

Plasma glucose was measured by a hexokinase method (Hitachi 911 automated analyzer; Boehringer Mannheim, Mannheim, Germany). HbA<sub>1c</sub> was measured by an automated ion-exchange chromatographic method (reference range 5.1–6.4%; Bio-Rad, Hercules, CA). Interassay and intra-assay coefficient of variation (CV) for HbA<sub>1c</sub> was  $\leq$ 3.1% at values <6.5%. Total cholesterol, triglycerides, and HDL cholesterol were measured by enzymatic methods on a Hitachi 911 automated analyzer using reagent kits supplied by the manufacturer of the analyzer. LDL cholesterol was calculated by the Friedewald's equation for triglyceride lev-

els <4.5 mmol/l (17). The precision performance of these assays was within the manufacturer's specifications. Urinary creatinine (Jaffe's kinetic method) and albumin (immunoturbidimetry method) were also measured on the Hitachi 911 analyzer using reagent kits supplied by the manufacturer. The interassay precision CV was 12.0 and 2.3% for urinary albumin concentrations of 8.0 mg/l and 68.8 mg/l, respectively. The lowest detection limit was 3.0 mg/l. Serum creatinine (Jaffe's kinetic method) was measured on a Dimension AR system (Dade Behring, Deerfield, IL). Serum ACE activity was measured by a modified spectrophotometric method with interassay and intra-assay CV <5% (18).

#### Genetic analysis

Genomic DNA was extracted from peripheral blood leukocytes. Genotyping for the ACE gene I/D polymorphism was performed using a PCR method as described previously (19). PCR amplification showed a 490-bp product (I allele) and/or 190-bp product (D allele) depending on the presence or absence of the insertion of a 278-bp fragment.

**Table 2—Genotype and allele frequencies of ACE I/D polymorphism in 1,281 Chinese patients with type 2 diabetes with or without occurrence of renal and cardiovascular end points**

	Status of renal end point		Status of cardiovascular end point	
	Nonoccurrence	Occurrence	Nonoccurrence	Occurrence
Genotype frequency				
II	559 (47.3)	36 (36.7)	524 (45.9)	71 (51.1)
DI	496 (41.9)	43 (43.9)	492 (43.1)	47 (33.8)
DD	128 (10.8)	19 (19.4)*	126 (11.0)	21 (15.1)
Total number of genotypes	1,183	98	1,142	139
Allele frequency				
I	1,614 (68.2)	115 (58.7)	1,540 (67.4)	189 (68.0)
D	752 (31.8)	81 (41.3)†	744 (32.6)	89 (32.0)
Total number of alleles	2,366	196	2,284	278

Data are *n* (%). Genotype and allele frequencies were compared by  $\chi^2$  test between patients with and without renal and cardiovascular end points. \* $P = 0.018$ , † $P = 0.006$  when the genotype and allele frequencies were compared between patients with and those without occurrence of renal end points, respectively.


### Statistical analysis

SPSS statistical software (version 9.0; SPSS, Chicago, IL) was used for statistical analysis with logarithmic transformation of skewed data including HbA<sub>1c</sub>, fasting blood glucose, triglycerides, serum creatinine, ACR, and AER. Continuous vari-

ables are expressed as means  $\pm$  SD or median (interquartile range) where appropriate. Between-group comparisons were analyzed using independent Student's *t* test and ANCOVA. The  $\chi^2$  test was used to analyze allele and genotype frequencies as well as the frequencies of di-

abetes complications. Cox regression model was used to estimate the hazard ratio (HR) with 95% CIs for mortality and clinical end points. Kaplan-Meier analysis was used to estimate the cumulative incidence of death and cardiovascular and renal outcomes. A *P* value  $<0.05$  (two-tailed) was considered significant.

**RESULTS**— A total of 1,281 (41.6% men, mean age  $61.0 \pm 12.0$  years) patients with mean follow-up duration of  $41.3 \pm 21.6$  months were enrolled for the analysis. The frequencies of normoalbuminuria, microalbuminuria, and macroalbuminuria in this prospective cohort were 56.7, 16.1, and 27.2%, respectively. Of these, 98 patients developed renal end points, whereas 139 patients developed cardiovascular end points. Patients who developed renal end points were older ( $65.2 \pm 11.1$  vs.  $60.6 \pm 12.1$  years,  $P < 0.001$ ), had longer duration of diabetes ( $9.6 \pm 5.2$  vs.  $8.3 \pm 6.7$  years,  $P = 0.025$ ), and were more likely to be men (52.9 vs. 41.4%,  $P = 0.03$ ). They also had higher systolic blood pressure ( $158 \pm 26$



**Figure 1—Cumulative renal end points of 1,281 Chinese patients with type 2 diabetes categorized according to their ACE polymorphism genotypes.**

**Table 3—Multiple Cox regression analysis to examine the predictors for renal and cardiovascular end points in 1,281 Chinese patients with type 2 diabetes**

Independent variables (at baseline)	HR	95% CI	P
<b>Renal end point</b>			
First model (without inclusion of serum ACE activity)			
Systolic blood pressure (mmHg)	1.02	1.01–1.03	<0.001
Ln value of triglycerides (mmol/l)	1.38	1.08–1.76	0.0098
Presence of diabetes complications at baseline*	6.99	4.41–11.07	<0.001
ACE genotype			0.004
DI genotype carriers of ACE gene I/D†	1.61	1.01–2.58	0.04
DD genotype carriers of ACE gene I/D‡	2.80	1.49–5.29	0.001
Second model (with serum ACE activity)			
Duration of diabetes (years)	1.07	1.02–1.12	0.005
Ln value of triglycerides (mmol/l)	2.65	1.72–4.07	<0.001
Presence of diabetes complications at baseline*	5.60	2.62–11.98	<0.001
ACE genotype			0.18
DI genotype carriers of ACE gene I/D†	2.51	0.84–7.49	0.19
DD genotype carriers of ACE gene I/D‡	2.46	0.36–16.55	0.12
<b>Cardiovascular end points</b>			
Age	1.10	1.06–1.09	<0.001
Systolic blood pressure (mmHg)	1.02	1.01–1.03	<0.001
LDL cholesterol (mmol/l)	1.24	1.05–1.45	0.009
Presence of diabetes complications at baseline*	2.12	1.43–3.14	0.0002

Dependent variable: renal end point defined as dialysis or doubling of baseline plasma creatinine or absolute value  $\geq 500 \mu\text{mol/l}$ . Independent variables for renal end points: age, duration of diabetes, systolic blood pressure, diastolic blood pressure, total cholesterol, ln value of triglycerides, presence of diabetes complications at baseline, and ACE gene I/D polymorphism II, DI, and DD genotype. Independent variables for cardiovascular end point: age, duration of diabetes, systolic blood pressure, diastolic blood pressure, ln value of triglycerides, LDL cholesterol, presence of diabetes complications at baseline, and ACE gene I/D polymorphism II, DI, and DD genotype. \*Presence of diabetes complications at baseline, including cardiovascular complications (ischemic heart disease, heart failure, stroke and/or peripheral vascular disease) or renal impairment with plasma creatinine  $\geq 150 \mu\text{mol/l}$  or presence of retinopathy. †DI genotype carriers compared with II genotype carriers. ‡DD genotype carriers compared with II genotype carriers.

vs.  $136 \pm 22 \text{ mmHg}$ ,  $P < 0.001$ ), greater waist-to-hip ratio ( $0.90 \pm 0.07$  vs.  $0.89 \pm 0.07$ ,  $P < 0.001$ ), more adverse lipid profile (total cholesterol  $6.2 \pm 1.6$  vs.  $5.5 \pm 1.2 \text{ mmol/l}$ ,  $P < 0.001$ ; triglycerides: median  $1.81$  [interquartile range  $1.25$ – $2.74$ ] vs.  $1.35 \text{ mmol/l}$  [ $0.91$ – $2.02$ ],  $P < 0.001$ ), less glycemic control ( $\text{HbA}_{1c}$   $8.1 \pm 2.2$  vs.  $7.9 \pm 1.9\%$ ,  $P < 0.001$ ), higher serum creatinine ( $199$  [ $150$ – $330$ ] vs.  $73 \mu\text{mol/l}$  [ $60$ – $91$ ],  $P < 0.001$ ), and AER ( $2,567.4$  [ $1,534.5$ – $4,139.1$ ] vs.  $16.7 \mu\text{g/min}$  [ $8.5$ – $154.0$ ],  $P < 0.001$ ) after adjustment for sex, age, and duration of diabetes. Patients who developed renal end points were also more likely to have retinopathy ( $77.9$  vs.  $33.1\%$ ,  $P < 0.001$ ) and cardiovascular disease ( $25.0$  vs.  $3.8\%$ ,  $P = 0.003$ ) at baseline and higher use of antihypertensive ( $66.3$  vs.  $29.2\%$ ,  $P < 0.001$ ) and lipid-lowering drugs ( $56.7$  vs.  $30.3\%$ ,  $P < 0.001$ ). Similarly, patients who developed cardiovascular end points had worse clinical profiles than patients who did not (data not shown). In this cohort, a

random sample of 399 patients underwent measurement of serum ACE activity. They had similar clinical characteristics as those in whom serum ACE activity was not available (data not shown).

The frequency was 67.5% for the I allele and 32.5% for the D allele; observed genotype frequencies were 46.4, 42.1, and 11.5% for the II, DI, and DD alleles, respectively. Genotype frequencies were in Hardy-Weinberg equilibrium. Table 1 summarizes the clinical and biochemical profiles of patients according to genotypes. They had comparable age, duration of diabetes, and anthropometric measurements, except that D allele carriers tended to have more cardiovascular complications and were more likely to be treated with antihypertensive and lipid-lowering drugs. In a subgroup of patients in whom serum ACE activity was available, DD ( $n = 40$ ) carriers had higher serum ACE activity than II ( $n = 193$ ) and DI ( $n = 166$ ) carriers (DD vs. DI vs. II,  $63.9 \pm 21.9$  vs.  $56.8 \pm 21.3$  vs.  $46.3 \pm 38.6$


units/l,  $P < 0.001$ ). There was a weak but significant correlation between AER and serum ACE activity ( $r = 0.12$ ,  $P = 0.003$ ).

Patients who developed renal end points had higher proportions of the DD genotype ( $19.4$  vs.  $10.8\%$ ,  $P = 0.018$ ) and D allele carriers ( $41.3$  vs.  $31.8\%$ ,  $P = 0.006$ ) than patients who did not (Table 2). The cumulative rates of renal end points were 10.0, 19.2, and 24.4% in II, DI, and DD carriers, respectively (Fig. 1). Using Cox regression analysis, ACE I/D polymorphism was an independent predictor for development of renal end points after controlling all confounding factors. Compared with patients with II genotype, DD genotype conferred an approximately threefold increased risk (HR 2.80 [95% CI 1.49–5.29],  $P = 0.001$ ), whereas DI genotype, a 1.6-fold increased risk (HR 1.61 [1.01–2.58],  $P = 0.04$ ) for renal end points. Other independent predictors included blood pressure, triglycerides, and underlying cardiovascular complications, renal impairment defined as plasma creatinine  $\geq 150 \mu\text{mol/l}$ , or presence of retinopathy at baseline. The conferred risk by DD/DI genotypes on renal end points became statistically insignificant when serum ACE activity was included in the model, whereas ACE activity per se was not an independent factor for renal events (HR 1.00 [0.98–1.02]) (Table 3).

Using Kaplan-Meier analysis, there was also a trend for DD carriers to develop more cardiovascular end points than II carriers (HR 1.27 [0.77–2.08]) but this did not reach statistical significance (Table 2 and Fig. 2). In the Cox regression analysis, age, blood pressure, LDL cholesterol, and presence of diabetes complications at baseline were independent risk factors for development of cardiovascular end points (Table 3).

**CONCLUSIONS**— In this prospective cohort of 1,281 Chinese patients with type 2 diabetes, we had demonstrated the deleterious effects of the D allele of the ACE I/D polymorphism on progression of nephropathy in addition to other risk factors such as blood pressure and lipid control as well as presence of diabetes complications. This is in accordance with recent findings that D allele was associated with development of nephropathy and structural kidney damage (9,20).

Albuminuria, blood pressure, and metabolic control are important promot-



**Figure 2**—Cumulative cardiovascular end points of 1,281 Chinese patients with type 2 diabetes categorized according to their ACE polymorphism genotypes.

ers of diabetic nephropathy, but these factors only accounted for approximately one-third of the variability (21). On the other hand, genetic factors had been shown to modulate risk of development of nephropathy in family studies (22). The ACE I/D polymorphism is one of the most extensively studied candidate genes and accounts for >40% of interindividual variability of serum or tissue ACE activity (23). In this respect, ACE activity is important in determining intrarenal angiotensin and kinin levels, which in turn control intraglomerular pressure and development of kidney damage via increased angiotensin II and probably reduced kinin formation (24,25). Increased serum ACE activity has been reported in both type 1 and type 2 diabetic patients with microalbuminuria (26,27). In addition, both animal and clinical studies have shown that ACE inhibition reduced intraglomerular pressure and attenuated the progression of nephropathy (28,29). In this study, patients with renal end points had more adverse metabolic profile, cardiovascular risk factors, renal impairment, albuminuria, and retinopathy at baseline. However, many of these associations were not selected as signifi-

cant independent variables in the multivariate model, possibly due to the overwhelming effect of cardiovascular complications that are known to be closely associated with multiple risk factors. Nevertheless, systolic blood pressure and log value of triglycerides remained significant predictors for renal end points after controlling for all these confounding variables. Notably, every 1-mmHg increment of systolic blood pressure and 1 log value of triglycerides was associated with a 1.02- and 1.38-fold increased risk, respectively. The results illustrated the importance of an integrated approach involving control of multiple risk factors in these high-risk patients.

On the other hand, after controlling for these confounding factors, the DD genotype remained an independent risk factor for renal end points, with an HR of 2.8. However, when serum ACE activity was included in the model, the independent predictive value of DD genotype lost its significance. In this connection, in keeping with other studies, we observed a small but significant association between serum ACE activity and AER, suggesting that the prognostic effect of ACE I/D polymorphism might be mediated, in part, by

ACE activity or possibly other closely associated factors that were not measured in this study.

In this cohort of 1,281 patients, there were 139 cardiovascular and 98 renal end points during a mean follow-up period of 41 months. These findings highlight the equally important roles of cardiovascular and renal events in Chinese compared with Caucasians, in whom cardiovascular morbidity and mortality predominate (30). It is now established that Caucasians have higher frequencies of the DD genotype, ranging from 32 to 42%, compared with 14–18% as reported in Asians (31–34). In our study, the prevalence of the DD genotype was 11.5%. Although these interethnic differences in genotype distribution have been put forward by some workers to explain the low prevalence of cardiovascular disease in Asians, the roles of ACE I/D polymorphism in hypertension and cardiovascular disease in Asians remain controversial (31,35–37). In this prospective cohort analysis, we observed a tendency for increased cardiovascular end points among DD genotype carriers, albeit short of significance.

Several potential limitations of this large-scale observational study warrant

further discussion. First, proteinuria and progression of nephropathy may be confounded by other factors, including changes in blood pressure, obesity, dyslipidemia, and glycemic control throughout the study period. In addition, adjustment of types and dosages of antihypertensive treatments, particularly ACE inhibitors, might confound the results given the weak but significant associations between AER and serum ACE activity. On the other hand, a previous study (38) suggested that serum ACE activity was an independent risk factor for development of cardiovascular end points along with other conventional risk factors. In our study, ACE activity was only measured in a small proportion of our patients, and further studies are required to address this issue. In this respect, survival bias due to premature death from cardiovascular disease among D allele carriers remains a possibility (8). Nevertheless, genotype distribution in our cohort was in Hardy-Weinberg equilibrium and the association between cardiovascular outcome and ACE I/D polymorphism was insignificant, suggesting minimal dropout. Despite these limitations, which would tend to weaken our results, we were able to demonstrate the prognostic significance of ACE I/D polymorphism, in addition to other conventional risk factors, in the progression of renal function in Chinese patients with type 2 diabetes.

In conclusion, in Chinese type 2 diabetic patients, the ACE D allele was associated with an increased risk of progression of nephropathy, which was mediated, in part, through its effect on serum ACE activity.

**Acknowledgments**—This study was supported by a CUHK Strategic Grant, Hong Kong Research Grant Committee Earmarked Grants, and the Hong Kong Innovation and Technology Fund (Grant ITS/033/00).

We thank Emily Poon, Stanley Ho, and Vincent Lam for their technical support. We thank Kevin H.M. Yu and Patricia Pinna for managing the Diabetes Database. Special thanks are extended to all staff at The Prince of Wales Hospital Diabetes and Endocrine Centre for recruiting and managing these patients. We also acknowledge the assistance by Dr. Fung Hong, Deputy Director, and Edwina Chu, Senior Statistician of the Hong Kong Hospital Authority Headquarters, in retrieving the data on clinical outcomes. We are grateful to all patients for donating their DNA to improve our understanding of these diseases.

## References

1. Peach MJ: Renin-angiotensin system: biochemistry and mechanisms of action. *Physiol Rev* 57:313–370, 1977
2. Corvol P, Williams TA, Soubrier F: Peptidyl dipeptidase A: angiotensin I-converting enzyme. *Methods Enzymol* 248:283–305, 1995
3. Ehlers MR, Fox EA, Strydom DJ, Riordan JF: Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. *Proc Natl Acad Sci U S A* 86:7741–7745, 1989
4. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 86:1343–1346, 1990
5. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, Myers RH, Levy D: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. *Circulation* 97:1766–1772, 1998
6. Dudley CR, Keavney B, Stratton IM, Turner RC, Ratcliffe PJ: U.K. Prospective Diabetes Study. XV: relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. *Kidney Int* 48:1907–1911, 1995
7. Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J: Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. *Diabetes Care* 18:983–985, 1995
8. Fava S, Azzopardi J, Ellard S, Hattersley AT: ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. *Diabetes Care* 24:2115–2120, 2001
9. Solini A, Dalla Vestra M, Saller A, Nosadini R, Crepaldi G, Fioletto P: The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. *Diabetes* 51:251–255, 2002
10. Ringel J, Beige J, Kunz R, Distler A, Sharma AM: Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. *Diabetologia* 40:193–199, 1997
11. Gutierrez C, Vendrell J, Pastor R, Llor C, Aguilar C, Broch M, Richart C: Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus: lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population. *Metabolism* 46:976–980, 1997
12. Young RP, Chan JC, Critchley JA, Poon E, Nicholls G, Cockram CS: Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. *Diabetes Care* 21:431–437, 1998
13. Wong TY, Chan JC, Poon E, Li PK: Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. *Am J Kidney Dis* 33:1064–1070, 1999
14. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M, for the Diabetes Care Monitoring Group of the St. Vincent Declaration Steering Committee: Monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the diabetes care initiative. *Diabet Med* 10:371–377, 1993
15. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjær H, Frøland A, Hansen KW, Nielsen S, Pedersen MM: Microalbuminuria and potential confounders. *Diabetes Care* 18:572–581, 1995
16. Laakso M, Pyörala K: Age of onset and type of diabetes. *Diabetes Care* 8:114–117, 1985
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18:499–502, 1972
18. Maguire GA, Price CP: A continuous monitoring spectrophotometric method for the measurement of angiotensin-converting enzyme in human serum. *Ann Clin Biochem* 22:204–210, 1985
19. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. *Nature* 359:641–644, 1992
20. Tarnow L, Gluud C, Parving HH: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. *Nephrol Dial Transplant* 13:1125–1130, 1998
21. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In *The Kidney*. 6th ed. Brenner BM, Levine S, eds. Philadelphia, WB Saunders, 2000, p. 1731–1773
22. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. *N Engl J Med* 320:

- 1161–1165, 1989
23. Tired L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. *Am J Hum Genet* 51: 197–205, 1992
  24. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC: Control of glomerular filtration rate by renin-angiotensin system. *Am J Physiol* 233:F366–F372, 1977
  25. Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F, Corvol P: Molecular biology of the angiotensin I converting enzyme: II. Structure-function: gene polymorphism and clinical implications. *J Hypertens* 11: 599–604, 1993
  26. Lieberman J, Sastre A: Serum angiotensin-converting enzyme: elevations in diabetes mellitus. *Ann Intern Med* 93:825–826, 1980
  27. Chan JC, Nicholls MG, Cheung CK, Law LK, Swaminathan R, Cockram CS: Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. *Diabetes Care* 18:1001–1006, 1995
  28. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. *J Clin Invest* 77:1925–1930, 1986
  29. Ravid M, Brosh D, Levi Z, Bar-Dayyan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. *Ann Intern Med* 128: 982–988, 1998
  30. Fuller JH, Stevens LK, Wang SL: Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia* 44 (Suppl. 2):S54–S64, 2001
  31. Thomas GN, Young RP, Tomlinson B, Woo KS, Sanderson JE, Critchley JA: Renin-angiotensin-aldosterone system gene polymorphisms and hypertension in Hong Kong Chinese. *Clin Exp Hypertens* 22:87–97, 2000
  32. Takahashi K, Nakamura H, Kubota I, Takahashi N, Tomoike H: Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan. *Jpn Heart J* 36:557–564, 1995
  33. Frost D, Pfohl M, Clemens P, Haring HU, Beischer W: Evaluation of the insertion/deletion ACE gene polymorphism as a risk factor for carotid artery intima-media thickening and hypertension in young type 1 diabetic patients. *Diabetes Care* 21: 836–840, 1998
  34. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. *N Engl J Med* 332:706–711, 1995
  35. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, Colman S, Leguennec S, MacMahon S, Neal B, Ohkubo T, Woodward M: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. *Hypertension* 42:297–303, 2003
  36. Ko YL, Ko YS, Wang SM, Chu PH, Teng MS, Cheng NJ, Chen WJ, Hsu TS, Kuo CT, Chiang CW, Lee YS: Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. *Hum Genet* 100:210–214, 1997
  37. Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M, Woo KS: Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. *Am Heart J* 137:653–657, 1999
  38. Cambien F, Costerousse O, Tired L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP, Luc G, Rakotavao R, Ducimetiere P, Soubrier F, Alhenc-Gelas F: Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. *Circulation* 90:669–676, 1994